Teva declines to comment on report it to make offer for Mylan

April 21, 2015 14:14


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Shares in generic drugmakers Teva Pharmaceutical Industries and Mylan jumped in pre-market trade in New York on a report from Bloomberg that Teva could make a public unsolicited offer for Mylan as soon as Tuesday.

A spokesman for Teva, the world's largest maker of generic drugs, said the company does not comment on rumors or reports.

According to Bloomberg, Teva is working with Barclays Plc on the approach. Officials at Barclays in Tel Aviv declined to comment.

Shares in Mylan were up 8.8 percent at $74 in premarket Nasdaq trade while Teva's New York Stock Exchange-listed shares were up 2.9 percent to $65.12.

Shares in Perrigo Co, which Mylan offered to buy for $29 billion this month, were down 4.5 percent at $189.20.

Mylan's chief executive said on Friday a merger with Teva would be a bad fit.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Breaking news
September 23, 2018
Kavanaugh accuser to testify Thursday in U.S. Senate